MedPath
EMA Product

Fiasp

Product approved by European Medicines Agency (EU)

Basic Information

Fiasp

Regulatory Information

EMEA/H/C/004046

Authorised

January 9, 2017

November 10, 2016

8

September 23, 2021

Company Information

Denmark

Novo Alle 2880 Bagsvaerd

Novo Nordisk A/S

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Overview Summary

Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a rapid-acting insulin.

© Copyright 2025. All Rights Reserved by MedPath